I would guess that AMRN management has an idea of what they think the company is worth even without expanded indication, and they feel the current pps is below that level. So that would make for a good long term buy no matter what happens Dec 20. I agree with Biolucky that AMRN may actually go up after FDA No vote. I have seen that before. AMRN has been beat down too far, No vote is priced in IMO.